EQ Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need...

Stats
Šios dienos apimtis	80 121.00
Vidutinė apimtis	367 004
Rinkos kapitalizacija	60.29M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $-0.170 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.50
ATR14	$0.0220 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Tom Penny	Sell	0	Common Stock
2024-03-06	Tom Penny	Sell	45 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	60 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)

INSIDER POWER
61.79
Last 97 transactions
Buy: 3 858 069 \| Sell: 577 250

Tūris Koreliacija

Ilgas: 0.02 (neutral)

Trumpas: 0.91 (very strong)

Signal:(45.935) Expect same movement, but be aware

Equillium Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GRNV	0.919
EGRX	0.917
AXTI	0.917
VVOS	0.915
FVE	0.909
BCRX	0.906
NVEE	0.904
OTRK	0.903
BFRI	0.903
CNSP	0.898

10 Labiausiai neigiamai susiję koreliacijos
AMRB	-0.94
LSTR	-0.939
RMBS	-0.937
LSCC	-0.936
MCHP	-0.932
KE	-0.93
SNSR	-0.926
SMH	-0.923
SOXX	-0.918
GRID	-0.917

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Equillium Inc Koreliacija - Valiuta/Žaliavos

-0.17
( neutral )

-0.27
( neutral )

0.00
( neutral )

0.22
( neutral )

0.01
( neutral )

-0.09
( neutral )

Equillium Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$36.08M
Bruto pelnas:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2023
Pajamos:	$36.08M
Bruto pelnas:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2022
Pajamos:	$15.76M
Bruto pelnas:	$15.64M (99.25 %)
EPS:	$-3.19

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.579

Financial Reports:

No articles found.

Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.